PHILADELPHIA and VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since...
NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce...
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Insiders intend to acquire up to approximately 10% of BriaCell’s basic common shares, or 1.59 million sharesCorporate buyback program will continue; 501,703 shares and 143,236 warrants repurchased...
NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 10.6 | 10.6 | 10.6 | 0 | 0 | CS |
4 | 0 | 0 | 10.6 | 10.6 | 10.6 | 0 | 0 | CS |
12 | 0 | 0 | 10.6 | 10.6 | 10.6 | 0 | 0 | CS |
26 | 0 | 0 | 10.6 | 10.6 | 10.6 | 0 | 0 | CS |
52 | 0 | 0 | 10.6 | 10.6 | 10.6 | 0 | 0 | CS |
156 | -2.7 | -20.3007518797 | 13.3 | 15.75 | 9.15 | 417 | 11.99521366 | CS |
260 | 10.56 | 26400 | 0.04 | 27 | 0.035 | 9004 | 2.33276443 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관